发布: 2017年05月20日第7卷第10期 DOI: 10.21769/BioProtoc.2277 浏览次数: 12548
评审: Lian Qun QiuAnonymous reviewer(s)
Abstract
Antigen-specific T cell-derived induced pluripotent stem cells (iPSCs) have been shown to re-differentiate into functional T cells and thus provide a potential source of T cells that could be useful for cancer immunotherapy. Human Vα24+ invariant natural killer T (Vα24+iNKT) cells are subset of T cells that are characterized by the expression of an invariant Vα24-Jα18 paired with Vβ11, that recognize glycolipids, such as α-galactosylceramide (α-GalCer), presented by the MHC class I-like molecule CD1d. Vα24+iNKT cells capable of producing IFN-γ are reported to augment anti-tumor responses, which affects both NK cells and CD8+ cytotoxic T lymphocytes to eliminate MHC- and MHC+ tumor cells, respectively. Here we describe a robust protocol to reprogram human Vα24+iNKT cells into iPSC, and then to re-differentiate them into Vα24+iNKT cells (iPS-Vα24+iNKT). We further provide a protocol to measure the activity of iPS-Vα24+iNKT cells.
Keywords: Induced pluripotent stem cell (诱导多能干细胞)Background
It was previously reported that clinical trials of Vα24+iNKT cell cancer immunotherapy targeting advanced non-small cell lung cancer (NSCLC) and head and neck cancer showed efficacy and were well-tolerated (Motohashi et al., 2009; Yamasaki et al., 2011). However, it has been known that the cell yield from ex vivo expansion of Vα24+iNKT cells from peripheral blood mononuclear cells (PBMCs) is often low (Motohashi et al., 2006). Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) using Yamanaka factors (Oct4, Sox2, Klf4 and c-Myc) has contributed greatly to the goals of regenerative medicine. The technology has recently been used to regenerate tumor-specific cytotoxic T lymphocytes and murine invariant natural killer T (iNKT) cells from iPSCs, thus opening up a new approach for cancer immunotherapy. Here, we have established a robust protocol to reprogram human Vα24+iNKT cells. We showed that iPS-derived Vα24+iNKT cells acted as cellular adjuvants and exerted anti-tumor activity, further extending their therapeutic potential. The complementation of other therapies with functionally validated Vα24+iNKT cells derived from iPSC could be valuable for cancer patients.
Materials and Reagents
Equipment
Software
Procedure
文章信息
版权信息
© 2017 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Yamada, D., Iyoda, T., Shimizu, K., Sato, Y., Koseki, H. and Fujii, S. (2017). Efficient Production of Functional Human NKT Cells from Induced Pluripotent Stem Cells − Reprogramming of Human Vα24+iNKT Cells. Bio-protocol 7(10): e2277. DOI: 10.21769/BioProtoc.2277.
分类
干细胞 > 多能干细胞 > 细胞诱导
免疫学 > 免疫细胞分化 > T 细胞
细胞生物学 > 细胞分离和培养 > 细胞分化
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link